loxo-783
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 11, 2022 (NCT05307705)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06102512 | Phase 1 | Oct 23, 2023 | Eli Lilly, Loxo Oncology |
| NCT06028425 | Phase 1 | Aug 2, 2023 | Eli Lilly, Loxo Oncology |
| NCT05894928 | Phase 1 | Jun 7, 2023 | Eli Lilly, Loxo Oncology |
| NCT05307705 | Phase 1 | May 11, 2022 | Eli Lilly, Loxo Oncology |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 4 | 1 | 2022 |
| Loxo Oncology | For profit | 4 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1